These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32495677)

  • 41. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
    Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
    J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
    Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
    Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-vitamin K vs vitamin K oral anticoagulants in patients aged > 80 year with atrial fibrillation and low body weight.
    Russo V; Attena E; Di Maio M; Carbone A; Parisi V; Rago A; Grieco FV; Buonauro A; Golino P; Nigro G
    Eur J Clin Invest; 2020 Nov; 50(11):e13335. PubMed ID: 32696449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients.
    Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Europace; 2020 Apr; 22(4):547-557. PubMed ID: 31598651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Kwon S; Lee SR; Choi EK; Choe WS; Lee E; Jung JH; Han KD; Oh S; Lip GYH
    Am Heart J; 2020 Nov; 229():81-91. PubMed ID: 32927313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry.
    Kim JY; Choi EK; Lim HE; Oh YS; Cho Y; On YK
    J Korean Med Sci; 2022 Dec; 37(48):e335. PubMed ID: 36513051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.
    Joosten LPT; van Maanen R; van den Dries CJ; Rutten FH; Hoes AW; Granger CB; Hemels MEW; Geersing GJ; van Doorn S
    Open Heart; 2023 May; 10(1):. PubMed ID: 37169490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme.
    Leblanc K; Bell AD; Ezekowitz JA; Tan MK; Laflamme D; Goldin L; Habert J; Lin PJ; Saunders K; Ngui D; Ng AP; Desroches J; Goodman SG;
    Int J Clin Pract; 2020 Dec; 74(12):e13625. PubMed ID: 33448547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial apixaban dosing in patients with atrial fibrillation.
    Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
    Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.